Viron's product pipeline is sustained through the identification of novel candidates and therapies by a dynamic in-house discovery program. PROSPECT^TM, PROtein Screen for Pathogen-Evolved Combination Therapeutics, is a proprietary leading edge platform with the ability to identify high quality drug candidates.  The PROSPECT^TM high throughput program is a streamlined process that focuses on the identification of new pipeline molecules that are of commercial interest to the pharmaceutical industry.